Topcare Chest Congestion and Cough Relief

Description

The drug is a pharmaceutical compound with a molecular weight of 300.45 g/mol and a chemical formula of C15H20N2O4S. It is formulated as a tablet for oral administration. The tablets are white to off-white in color and are round in shape. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, and magnesium stearate.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with minor throat and bronchial irritation, which may occur due to a common cold. It aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating the clearance of bothersome mucus from the bronchial passageways. Additionally, this medication helps to make coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children 12 years of age and over are instructed to take 1 tablet every 4 hours as needed. For children aged 6 to under 12 years, the recommended dosage is 1/2 tablet every 4 hours as needed. It is important to note that for children under 6 years of age, consultation with a doctor is required prior to administration.

Healthcare professionals should advise patients not to exceed 6 doses within a 24-hour period, unless otherwise directed by a physician.

Contraindications

Use of this product is contraindicated in the following situations:

• Patients currently taking a prescription monoamine oxidase inhibitor (MAOI).

• Patients taking specific medications for depression, psychiatric or emotional conditions, or Parkinson's disease.

• Use is contraindicated for 2 weeks following the discontinuation of an MAOI. If there is uncertainty regarding the presence of an MAOI in a prescription medication, consultation with a healthcare professional is advised prior to use.

Warnings and Precautions

Use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing an MAOI. Healthcare professionals should advise patients to consult their doctor or pharmacist if they are uncertain whether their prescription medication contains an MAOI.

Patients should be cautioned to seek medical advice prior to using this product if they have a persistent or chronic cough, particularly if it is associated with smoking, asthma, bronchitis, or emphysema. Additionally, if the cough is accompanied by excessive phlegm (mucous), medical consultation is recommended.

In the event of an overdose, it is imperative to seek emergency medical assistance or contact a Poison Center immediately.

Patients should discontinue use and consult their healthcare provider if they experience any of the following: symptoms accompanied by fever, rash, or a persistent headache; a cough that persists for more than one week; or a cough that tends to recur. A persistent cough may indicate a serious underlying condition that requires further evaluation.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. Serious adverse reactions include the potential for significant interactions with monoamine oxidase inhibitors (MAOIs). It is contraindicated to use this medication concurrently with a prescription MAOI or within two weeks of discontinuing an MAOI.

Common adverse reactions may arise, particularly in patients with specific pre-existing conditions. Patients should be advised to stop use and consult a healthcare professional if symptoms are accompanied by fever, rash, or a persistent headache. Additionally, if a cough persists for more than one week or tends to recur, it may indicate a serious underlying condition, warranting further medical evaluation.

Before initiating treatment, patients should seek medical advice if they have a persistent or chronic cough, such as that associated with smoking, asthma, bronchitis, or emphysema. Furthermore, if the cough is accompanied by excessive phlegm (mucous), it is essential to consult a healthcare provider prior to use.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not use this product while taking an MAOI or for a period of two weeks following the discontinuation of an MAOI.

MAOIs are commonly prescribed for the treatment of depression, certain psychiatric or emotional conditions, and Parkinson's disease. It is essential for patients to verify whether their current prescription medications contain an MAOI. If there is any uncertainty regarding the presence of an MAOI in their medication regimen, patients are advised to consult their healthcare provider or pharmacist prior to using this product.

Packaging & NDC

Below are the non-prescription pack sizes of Topcare Chest Congestion and Cough Relief (dextromethorphan hydrobromide / guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may take 1/2 tablet every 4 hours as needed. For children under 6 years of age, consultation with a doctor is advised prior to use. In contrast, adults and children 12 years of age and older are recommended to take 1 tablet every 4 hours as needed. It is important to note that no more than 6 doses should be administered within a 24-hour period, unless otherwise directed by a healthcare professional.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Close monitoring is recommended to ensure safety and efficacy in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits associated with the use of this drug during pregnancy and lactation. The safety profile in these populations has not been fully established, and healthcare providers should consider individual circumstances when advising patients.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may involve the following steps:

1. Assessment: Conduct a thorough evaluation of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide symptomatic treatment as necessary, which may include intravenous fluids, oxygen supplementation, or medications to stabilize the patient's condition.

3. Decontamination: If the overdose is recent, consider gastrointestinal decontamination methods such as activated charcoal, provided the patient is alert and able to protect their airway.

4. Consultation: Engage with a poison control center or toxicology expert for guidance on specific interventions and antidotes, if applicable.

Healthcare professionals should remain vigilant and prepared to implement these management strategies in the event of an overdose, even in the absence of specific overdosage data.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children and to seek immediate medical assistance or contact a Poison Center in the event of an overdose.

Patients should be informed not to use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of stopping an MAOI. If patients are uncertain whether their prescription medication contains an MAOI, they should be encouraged to consult their doctor or pharmacist prior to using this product.

Healthcare providers should instruct patients to discontinue use and consult a doctor if their symptoms are accompanied by fever, rash, or a persistent headache. Additionally, patients should be advised to seek medical attention if a cough persists for more than one week or tends to recur, as a persistent cough may indicate a serious underlying condition.

It is also important for healthcare providers to recommend that patients consult their doctor before using this product if they have a persistent or chronic cough, such as that associated with smoking, asthma, bronchitis, or emphysema, or if their cough is accompanied by excessive phlegm (mucous).

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available upon request. It is essential to store the product at a temperature range of 15°C to 30°C (59°F to 86°F) to maintain its efficacy and stability. Proper container requirements should be adhered to, ensuring that the product is kept in a suitable environment. Special handling needs should be observed to prevent exposure to conditions outside the recommended temperature range.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. It is important to keep the medication out of reach of children, and in the event of an overdose, patients should seek medical assistance or contact a Poison Center immediately.

Drug Information (PDF)

This file contains official product information for Topcare Chest Congestion and Cough Relief, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)